MX2017002705A - Sondas para la proyección de imagen de la proteína huntingtina. - Google Patents

Sondas para la proyección de imagen de la proteína huntingtina.

Info

Publication number
MX2017002705A
MX2017002705A MX2017002705A MX2017002705A MX2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A MX 2017002705 A MX2017002705 A MX 2017002705A
Authority
MX
Mexico
Prior art keywords
probes
huntingtin protein
imaging
imaging huntingtin
protein
Prior art date
Application number
MX2017002705A
Other languages
English (en)
Inventor
Dominguez Celia
John Brown Christopher
Wityak John
Bard Jonathan
Edward Prime Michael
David Johnson Peter
Clark Frew Daniel
Rene Gabriel Galan Sebastien
Richard Giles Paul
Alexander Weddell Derek
Simon Walter Daryl
James WIGGINTON Ian
George Taylor Malcolm
Martin KRÜLLE Thomas
Morao Inaki
Original Assignee
Chdi Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc filed Critical Chdi Foundation Inc
Publication of MX2017002705A publication Critical patent/MX2017002705A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0419—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Furan Compounds (AREA)

Abstract

Se proporcionan agentes de formación de imágenes que comprenden un compuesto de la Fórmula I, o su sal farmacéuticamente aceptable, y métodos de su uso.
MX2017002705A 2014-08-29 2015-08-28 Sondas para la proyección de imagen de la proteína huntingtina. MX2017002705A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043617P 2014-08-29 2014-08-29
PCT/US2015/047427 WO2016033460A1 (en) 2014-08-29 2015-08-28 Probes for imaging huntingtin protein

Publications (1)

Publication Number Publication Date
MX2017002705A true MX2017002705A (es) 2017-12-20

Family

ID=55400659

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002705A MX2017002705A (es) 2014-08-29 2015-08-28 Sondas para la proyección de imagen de la proteína huntingtina.

Country Status (14)

Country Link
US (1) US10907197B2 (es)
EP (1) EP3190888B1 (es)
JP (1) JP2017528520A (es)
KR (1) KR20170047341A (es)
CN (1) CN107105655A (es)
AU (2) AU2015308709B2 (es)
BR (1) BR112017004134A2 (es)
CA (1) CA2959505A1 (es)
EA (1) EA201790408A1 (es)
ES (1) ES2818107T3 (es)
IL (1) IL250804A0 (es)
MX (1) MX2017002705A (es)
SG (1) SG11201701580XA (es)
WO (1) WO2016033460A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6754353B2 (ja) 2014-08-29 2020-09-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
ES2898965T3 (es) 2014-08-29 2022-03-09 Chdi Foundation Inc Sondas de formación de imágenes de la proteína Huntingtina
US11071793B2 (en) 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein
CN106632002A (zh) * 2016-09-28 2017-05-10 贵州大学 一种依托考昔及其对照品5‑氯‑3‑(4‑(甲基磺酰基)苯基)‑2,3‑联吡啶的制备工艺
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
CN108178764A (zh) * 2018-01-09 2018-06-19 天津科技大学 呋喃并[2,3-b]吡啶类化合物及无金属催化的合成方法
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1367836A (en) * 1918-04-29 1921-02-08 Int Precipitation Co Process for obtaining chlorids of potassium or other metals
US3985755A (en) * 1972-06-02 1976-10-12 E. R. Squibb & Sons, Inc. Pyridine containing isothiocyanobenzoxazoles
FR2524468B1 (fr) * 1982-04-06 1985-10-18 Sandoz Sa Nouveaux derives condenses du thiophene, leur preparation et leur utilisation comme azurants optiques
JPS60146877A (ja) * 1984-01-11 1985-08-02 Chisso Corp ２―置換―６―（５―置換―２―ピリミジニル）ナフタリン
JPH11171886A (ja) * 1997-12-08 1999-06-29 Mitsui Chem Inc アミジンまたはグアニジンを側鎖にもつピロリルベンズイミダゾール誘導体
EP1455779B1 (en) * 2001-12-20 2006-08-09 Wyeth Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
DK1611115T3 (da) * 2003-03-14 2012-11-26 Univ Pittsburgh Benzothiazolderivatforbindelser, sammensætninger og anvendelser deraf
JP2007504283A (ja) * 2003-05-20 2007-03-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア β−アミロイド斑に作用物質を結合させる方法
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
BRPI0716583A2 (pt) 2006-08-24 2013-10-01 Australian Nuclear Science Tec ligandos fluorados para marcar recptores de benzodiazepina perifÉricos
WO2008134618A2 (en) * 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
KR101469275B1 (ko) 2007-06-01 2014-12-08 재단법인서울대학교산학협력재단 베타아밀로이드 침착의 영상화를 위한 헤테로사이클릭 인덴계열의 유도체 및 그의 방사성 동위원소 표지화합물
US20090123373A1 (en) 2007-11-05 2009-05-14 Yanming Wang Amyloid-imaging agents
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
WO2009146388A1 (en) * 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
WO2009155017A2 (en) * 2008-05-30 2009-12-23 Merck & Co., Inc. Novel substituted azabenzoxazoles
EP2341909A4 (en) * 2008-10-31 2012-05-30 Merck Sharp & Dohme NEW SUBSTITUTED AZABENZOXAZOLE
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
GB0905664D0 (en) 2009-04-02 2009-05-13 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP5615902B2 (ja) 2009-04-02 2014-10-29 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ）Ｃｅｎｔｒｏ Ｎａｃｉｏｎａｌ Ｄｅ Ｉｎｖｅｓｔｉｇａｃｉｏｎｅｓ Ｏｎｃｏｌｏｇｉｃａｓ（Ｃｎｉｏ） イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
WO2011045415A2 (en) * 2009-10-15 2011-04-21 Guerbet New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する２−アリールベンゾオキサゾール化合物
ES2898965T3 (es) 2014-08-29 2022-03-09 Chdi Foundation Inc Sondas de formación de imágenes de la proteína Huntingtina
US11071793B2 (en) 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
JP6754353B2 (ja) 2014-08-29 2020-09-09 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
DK3340796T3 (da) 2015-08-28 2021-07-26 Chdi Foundation Inc Sonder til afbildning af huntingtin-protein

Also Published As

Publication number Publication date
US20170292150A1 (en) 2017-10-12
CN107105655A (zh) 2017-08-29
EP3190888A1 (en) 2017-07-19
IL250804A0 (en) 2017-04-30
AU2020202226A1 (en) 2020-04-16
EP3190888A4 (en) 2018-05-09
KR20170047341A (ko) 2017-05-04
US10907197B2 (en) 2021-02-02
SG11201701580XA (en) 2017-03-30
ES2818107T3 (es) 2021-04-09
CA2959505A1 (en) 2016-03-03
AU2015308709A1 (en) 2017-03-23
JP2017528520A (ja) 2017-09-28
WO2016033460A1 (en) 2016-03-03
BR112017004134A2 (pt) 2017-12-12
EP3190888B1 (en) 2020-06-10
EA201790408A1 (ru) 2017-09-29
AU2015308709B2 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MX2021003311A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2021005891A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
MX2017002702A (es) Sondas para la proyección de imagen de la proteína huntingtina.
CL2017001566A1 (es) Derivados de azabiciclootano como agonistas de fxr para el uso en el tratamiento de enfermedades hepáticas y gastrointestinales.
MX2018002338A (es) Sondas para formar imagenes de proteina de huntingtina.
MX2017002705A (es) Sondas para la proyección de imagen de la proteína huntingtina.
TW201613872A (en) IRAK4 inhibiting agents
HK1251546A1 (zh) S-氯胺酮的(s)-csa鹽、s-氯胺酮的(r)-csa鹽和用於製備s-氯胺酮的方法
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CY1121464T1 (el) Στεροειδης ενωση για χρηση στην αντιμετωπιση της ηπατικης εγκεφαλοπαθειας
IL259952A (en) Use of tryptophan derivatives for protein formulations
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
WO2015179823A3 (en) Lung localized inhibitors of alpha(v)beta 6
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
EP3218721A4 (en) Compounds for use as imaging agents
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
IL246835A0 (en) Improved process for the preparation of trazodone and its hydrochloride salt
WO2015179349A3 (en) Synthesis of beta-arrestin effectors
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
IT201700024657A1 (it) Materassino per operazioni chirurgiche.
PL3224253T3 (pl) Pochodne bis(sulfonoamidu) i ich zastosowanie jako inhibitorów mpges